La Jol­la feels the burn of ri­val malar­ia ap­proval; With an­oth­er $10B, Bay­er could fi­nal­ly weed out its her­bi­cide prob­lem

→ La Jol­la Phar­ma­ceu­ti­cal‘s shares $LJPC tum­bled about 20% to $5.48 on Wednes­day morn­ing af­ter an­oth­er com­pa­ny — Mary­land-based Ami­vas — was grant­ed FDA ap­proval for an …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER